Ellsworth Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL

Key Points

• Ellsworth Advisors LLC purchased 97,208 shares of Exelixis, Inc. for approximately $3,589,000 in the first quarter, highlighting continued interest from institutional investors.
• Exelixis has a consensus rating of "Moderate Buy" among analysts, with a target price averaging $44.06, reflecting positive sentiment despite a recent drop in stock value.
• Exelixis reported earnings of $0.75 per share for the last quarter, exceeding estimates, but experienced a 10.8% revenue decline compared to the previous year.

Ellsworth Advisors LLC bought a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 97,208 shares of the biotechnology company's stock, valued at approximately $3,589,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Hemington Wealth Management grew its stake in Exelixis by 211.3% during the 1st quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 522 shares in the last quarter. Bartlett & CO. Wealth Management LLC bought a new stake in shares of Exelixis in the 1st quarter valued at approximately $37,000. Costello Asset Management INC bought a new stake in shares of Exelixis in the 1st quarter valued at approximately $39,000. Harbour Investments Inc. grew its stake in shares of Exelixis by 900.0% in the 1st quarter. Harbour Investments Inc. now owns 1,100 shares of the biotechnology company's stock valued at $41,000 after buying an additional 990 shares in the last quarter. Finally, McIlrath & Eck LLC bought a new stake in shares of Exelixis in the 1st quarter valued at approximately $52,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Trading Up 0.2%

Shares of EXEL traded up $0.08 during trading hours on Friday, hitting $39.15. 2,475,619 shares of the stock traded hands, compared to its average volume of 2,200,644. Exelixis, Inc. has a 1-year low of $25.17 and a 1-year high of $49.62. The firm has a market capitalization of $10.54 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32. The business has a fifty day moving average of $39.97 and a 200-day moving average of $39.64.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.63 by $0.12. Exelixis had a return on equity of 27.47% and a net margin of 27.01%.The business had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. During the same quarter in the prior year, the firm posted $0.84 earnings per share. The firm's revenue for the quarter was down 10.8% compared to the same quarter last year. Exelixis has set its FY 2025 guidance at EPS. As a group, equities research analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on EXEL. Bank of America boosted their price target on Exelixis from $45.00 to $46.00 and gave the company a "neutral" rating in a research note on Thursday, June 5th. Benchmark reissued a "neutral" rating on shares of Exelixis in a research note on Monday, June 23rd. Morgan Stanley lowered their price target on Exelixis from $48.00 to $46.00 and set an "overweight" rating for the company in a research note on Tuesday, July 29th. Guggenheim restated a "buy" rating and issued a $45.00 target price on shares of Exelixis in a report on Tuesday, July 29th. Finally, Barclays upped their price target on Exelixis from $29.00 to $40.00 and gave the stock an "equal weight" rating in a report on Thursday, July 10th. Thirteen analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus target price of $44.06.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.